In accordance with Section 29 of the Securities Trading Act, Novo Nordisk hereby reports that on 5 September 2008 Novo Nordisk received notification from The Capital Group Companies that their total shareholding in Novo Nordisk is now below the threshold of 10%. The Capital Group Companies now holds 63,273,181 B shares of DKK 1 equal to 9.98% of the total share capital in Novo Nordisk, corresponding to 3.95% of the voting rights.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,300 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
Further information:
|
Media: |
Investors: |
|
|
|
|
Elin K Hansen |
Mads Veggerby Lausten |
|
Tel (direct): (+45) 4442 3450 |
Tel (direct): (+45) 4443 7919 |
|
|
|
|
|
Hans Rommer |
|
|
Tel (direct): (+45) 4442 4765 |
|
|
|
|
In North America: |
|
|
Sean Clements |
|
|
Tel (direct): (+1) 609 514 8316 |
|
|
|
Company Announcement no 58 / 2008